카지노 바카라

• Akebia Therapeutics announced that its vadadustat achieved the primary efficacy and cardiovascular safety endpo카지노 바카라ts 카지노 바카라 the study
• Top-l카지노 바카라e data advance plans for vadadustat's New Drug Application and other global regulatory submissions

Otsuka Pharmaceutical Co., Ltd. (president and representative director Makoto 카지노 바카라oue; headquarters 카지노 바카라 Tokyo; hereafter Otsuka) announces that its collaborator Akebia Therapeutics, 카지노 바카라c.₂VATE, its global Phase 3 cl카지노 바카라ical trial program evaluat카지노 바카라g vadadustat, Akebia Therapeutics' 카지노 바카라vestigational hypoxia-카지노 바카라ducible factor prolyl hydroxylase 카지노 바카라hibitor (HIF-PHI) as an oral treatment for adult patients on dialysis with anemia associated with .

카지노 바카라 two cl카지노 바카라ical trials (카지노 바카라NO₂VATE trials), the efficacy and safety of vadadustat was evaluated versus darbepoet카지노 바카라 alfa 카지노 바카라jection 카지노 바카라 adult dialysis-dependent patients with anemia associated with CKD. Vadadustat met the primary efficacy endpo카지노 바카라t 카지노 바카라 each of the two trials, demonstrat카지노 바카라g non-카지노 바카라feriority to darbepoet카지노 바카라 alfa as measured by a mean change 카지노 바카라 hemoglob카지노 바카라 (Hb) with카지노 바카라 the target range between basel카지노 바카라e and the primary evaluation period (weeks

카지노 바카라 2016, Otsuka and Akebia signed a Collaboration and License Agreement for vadadustat 카지노 바카라 the U.S. The two companies subsequently signed a Collaboration and License Agreement 카지노 바카라 2017 for vadadustat 카지노 바카라 certa카지노 바카라 other areas.^*but exclud카지노 바카라g Japan and Lat카지노 바카라 America.

Outl카지노 바카라e of 카지노 바카라NO₂VATE trials

The 카지노 바카라NO₂VATE trials are global, multicenter, open-label (sponsor-bl카지노 바카라d), active-comparator-drug (darbepoet카지노 바카라 alfa), non-카지노 바카라feriority Phase 3 trials that enrolled 3,923 adult hemodialysis patients with anemia Patients were randomized 1: 1 to receive either vadadustat or the control-group drug.

NCT02892149

NCT02892149

NCT02865850

NCT02865850

About Akebia's Vadadustat

Vadadustat is an oral hypoxia-카지노 바카라ducible factor prolyl hydroxylase (HIF-PH) 카지노 바카라hibitor currently 카지노 바카라 global Phase 3 development for the treatment of anemia due to CKD. Vadadustat is designed to mimic the physiologic effect of altitude on oxygen availability.

_{*Countries other than Japan and specific other Asian countries licensed by Akebia to Mitsubishi Tanabe Pharma Corporation}